#weight-loss-drug
#weight-loss-drug

[ follow ]

F.D.A. Approves Weight-Loss Drug to Treat Sleep Apnea

Zepbound is the first ever FDA-approved medication for treating obstructive sleep apnea, particularly aimed at those with obesity.

Here's how Eli Lilly is fixing its Zepbound supply shortage

Eli Lilly has begun selling starter doses of Zepbound in vials online to boost supply and accessibility.

Weight-Loss Drugs Help Sleep Apnea Symptoms

Zepbound, Eli Lilly's weight-loss drug, showed promising results in reducing breathing problems in patients with obstructive sleep apnea, potentially increasing insurance coverage.

Eli Lilly raises price of Zepbound while trumpeting discount on starter vials

Eli Lilly's Zepbound pricing strategy has both improved access with lower starter dosages while raising concerns over transparency with existing drug prices.

Zepbound shortage update: FDA issues 'limited availability' warning. When might it end?

Zepbound, a weight loss drug by Eli Lilly, facing shortage in certain doses in the U.S. due to increased demand.

F.D.A. Approves Weight-Loss Drug to Treat Sleep Apnea

Zepbound is the first ever FDA-approved medication for treating obstructive sleep apnea, particularly aimed at those with obesity.

Here's how Eli Lilly is fixing its Zepbound supply shortage

Eli Lilly has begun selling starter doses of Zepbound in vials online to boost supply and accessibility.

Weight-Loss Drugs Help Sleep Apnea Symptoms

Zepbound, Eli Lilly's weight-loss drug, showed promising results in reducing breathing problems in patients with obstructive sleep apnea, potentially increasing insurance coverage.

Eli Lilly raises price of Zepbound while trumpeting discount on starter vials

Eli Lilly's Zepbound pricing strategy has both improved access with lower starter dosages while raising concerns over transparency with existing drug prices.

Zepbound shortage update: FDA issues 'limited availability' warning. When might it end?

Zepbound, a weight loss drug by Eli Lilly, facing shortage in certain doses in the U.S. due to increased demand.

Nurse's death linked to approved weight-loss drug

The death of nurse Susan McGowan has raised concerns over the safety of the weight-loss drug Mounjaro, linked to her unexpected health decline.

BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq

BioAge Labs is entering the public market with its obesity drug Azelaprag in clinical trials, aiming for significant growth and competition in the weight loss sector.

Users of New Weight Loss Drug Had Lower Blood Pressure in Study

Tirzepatide, a weight loss drug, was found to significantly lower blood pressures after 36 weeks of use.

The study assessed tirzepatide's effects on weight loss and found that participants taking the drug had lower blood pressures when measured with a 24-hour monitor.

[ Load more ]